Status:
COMPLETED
Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction
Lead Sponsor:
Miles Berger, MD PhD
Conditions:
Postoperative Delirium
Postoperative Cognitive Dysfunction
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
This research study will evaluate the effectiveness and estimate the feasibility of administering an investigational drug called 'CN-105' (the study drug), to prevent postoperative cognitive decline, ...
Detailed Description
This research study will evaluate the effectiveness and estimate the feasibility of administering an investigational drug called 'CN-105' (the study drug), to prevent postoperative cognitive decline, ...
Eligibility Criteria
Inclusion
- Age ≥ 60
- Ability to speak English
- Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last \> 2 hours; due to be admitted to the hospital following surgery
Exclusion
- Inmate of a correctional facility
- Scheduled to receive systemic chemotherapy between the time of the two cognitive testing sessions
- Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other clinical contraindication known ahead of time.
- Inappropriate for study inclusion based on the judgement of the principal investigator.
- If a patient undergoes major head trauma that occurs between the times of the two cognitive testing sessions, then they will be withdrawn from the study.
Key Trial Info
Start Date :
July 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2022
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT03802396
Start Date
July 15 2018
End Date
December 28 2022
Last Update
October 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Hospital
Durham, North Carolina, United States, 27710